We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Pulmonary Arterial Hypertension in Systemic Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00617487
Recruitment Status : Active, not recruiting
First Posted : February 18, 2008
Last Update Posted : March 7, 2018
Information provided by (Responsible Party):
Carlomaurizio Montecucco, IRCCS Policlinico S. Matteo

Brief Summary:
The purpose of this study is to evaluate the role of stress echocardiography, compared to standard echocardiography in the early identification of pulmonary arterial hypertension in systemic sclerosis. To evaluate the role of BNP in this setting.To analyze data recorded with respect to the parameters commonly used for SSc evaluation (eg thorax HRCT, pulmonary function tests + DLCO, nailfold capillaroscopy, etc); these parameters are available starting for 1999.

Condition or disease
Systemic Sclerosis Pulmonary Arterial Hypertension

Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Stress Echocardiography in the Early Identification of Pulmonary Arterial Hypertension in Systemic Sclerosis
Study Start Date : December 2007
Estimated Primary Completion Date : March 2018
Estimated Study Completion Date : January 2020

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patients with systemic sclerosis

Inclusion Criteria:

  • Patients with systemic sclerosis according to LeRoy criteria

Exclusion Criteria:

  • Pregnancy
  • Significant valvular disease
  • Low left ventricular function upon echocardiography (ejection fraction<55%)
  • History of atrial fibrillation, myocardial infarction, pulmonary thromboembolisms, neoplasia or severe hepatic disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00617487

IRCCS Foundation Policlinico S. Matteo
Pavia, PV, Italy, 27100
IRCCS Policlinico S. Matteo
Pavia, PV, Italy, 27100
Sponsors and Collaborators
IRCCS Policlinico S. Matteo
Study Director: Stefano Ghio, MD IRCCS Foundation Policlinico S. Matteo, Cardiology
Principal Investigator: Lorenzo Cavagna, MD University and IRCCS Foundation Policlinico S. Matteo, Rheumatology

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Carlomaurizio Montecucco, Director, Dept. of Rheumatology, IRCCS Policlinico S. Matteo
ClinicalTrials.gov Identifier: NCT00617487     History of Changes
Other Study ID Numbers: EchostressSSc
First Posted: February 18, 2008    Key Record Dates
Last Update Posted: March 7, 2018
Last Verified: March 2018

Additional relevant MeSH terms:
Familial Primary Pulmonary Hypertension
Scleroderma, Systemic
Scleroderma, Diffuse
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases
Connective Tissue Diseases
Skin Diseases